Your browser doesn't support javascript.
Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement.
Rong, Heng; Qi, Mi; Pan, Jingdi; Sun, Yuhan; Gao, Jiawang; Zhang, Xiaowei; Li, Wei; Zhang, Bo; Zhang, Xian-En; Cui, Zongqiang.
  • Rong H; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Qi M; University of Chinese Academy of Sciences, Beijing, China.
  • Pan J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Sun Y; University of Chinese Academy of Sciences, Beijing, China.
  • Gao J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Zhang X; University of Chinese Academy of Sciences, Beijing, China.
  • Li W; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Zhang B; University of Chinese Academy of Sciences, Beijing, China.
  • Zhang XE; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Cui Z; University of Chinese Academy of Sciences, Beijing, China.
Front Immunol ; 13: 905431, 2022.
Article in English | MEDLINE | ID: covidwho-1883914
ABSTRACT
The Zika virus (ZIKV) epidemic poses a substantial threat to the public, and the development of safe and effective vaccines is a demanding challenge. In this study, we constructed a kind of self-assembling nanovaccine which confers complete protection against ZIKV infection. The ZIKV envelop protein domain III (zEDIII) was presented on recombinant human heavy chain ferritin (rHF) to form the zEDIII-rHF nanoparticle. Immunization of mice with zEDIII-rHF nanoparticle in the absence of an adjuvant induced robust humoral and cellular immune responses. zEDIII-rHF vaccination conferred complete protection against lethal infection with ZIKV and eliminated pathological symptoms in the brain. Importantly, the zEDIII-rHF nanovaccine induced immune response did not cross-react with dengue virus-2, overcoming the antibody-dependent enhancement (ADE) problem that is a safety concern for ZIKV vaccine development. Our constructed zEDIII-rHF nanovaccine, with superior protective performance and avoidance of ADE, provides an effective and safe vaccine candidate against ZIKV.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Zika Virus / Zika Virus Infection Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.905431

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Zika Virus / Zika Virus Infection Type of study: Randomized controlled trials Topics: Vaccines Limits: Animals Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.905431